scPharmaceuticals (SCPH)
(Real Time Quote from BATS)
$5.45 USD
-0.07 (-1.27%)
Updated Aug 5, 2025 10:34 AM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SCPH 5.45 -0.07(-1.27%)
Will SCPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SCPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SCPH
scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
SCPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for SCPH
scPharmaceuticals Holds Annual Stockholders Meeting June 2025
scPharmaceuticals: Furoscix Sales To Accelerate Throughout 2025
Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), 10x Genomics (TXG) and Kura Oncology (KURA)
Craig-Hallum Sticks to Its Buy Rating for scPharmaceuticals (SCPH)
scPharmaceuticals Earnings Call Highlights Growth and Expansion